Mean FFbH after 6–24 months for completers of the initial biological therapy and for all patients (ITT analysis)
| Completers only | All patients | |||||
| n | Mean of FFbH at 6, 12, 18, 24 months (95% CI) | Mean of FFbH at 6, 12, 18, 24 months (95% CI) | n | Mean of FFbH at 6, 12, 18, 24 months (95% CI) | Mean of FFbH at 6, 12, 18, 24 months (95% CI) | |
| Unadjusted | Adjusted* | Unadjusted | Adjusted* | |||
| ETA/MTX | 182 | 69.9 (66.9 to 73.0) | 68.2 (66.1 to 70.2) | 305 | 65.9 (63.4 to 68.4) | 65.2 (63.6 to 66.7) |
| ETA/LEF | 49 | 71.7 (65.7 to 77.6) | 69.2 (65.2 to 73.1) | 78 | 66.0 (61.1 to 71.0) | 65.6 (62.4 to 68.7) |
| ADA/MTX | 156 | 69.8 (66.5 to 73.1) | 67.6 (65.2 to 69.9) | 274 | 66.0 (63.4 to 68.7) | 65.1 (63.3 to 66.9) |
| ADA/LEF | 40 | 67.9 (61.4 to 74.5) | 67.0 (62.5 to 71.4) | 80 | 62.9 (58.0 to 67.8) | 63.0 (59.9 to 66.2) |
| INF/MTX | 112 | 70.8 (66.8 to 74.7) | 71.2 (68.5 to 73.8) | 250 | 65.3 (62.6 to 68.1) | 66.8 (65.0 to 68.6) |
| INF/LEF | 19 | 69.2 (59.7 to 78.8) | 66.5 (60.2 to 72.7) | 54 | 67.4 (61.4 to 73.3) | 64.2 (60.3 to 68.0) |
| MTX total | 68.9 (67.6 to 70.2) | 65.9 (64.9 to 66.8) | ||||
| LEF total | 67.7 (64.9 to 70.6) | 64.1 (62.1 to 66.0) | ||||
*Means adjusted for disease activity score based on 28 joint counts (DAS28) at baseline, function, percentage of men, previous biological therapy, year of follow-up, year of study entry; see Statistics section.
ADA, adalimumab; ETA, etanercept; FFbH, Hannover functional status questionnaire; INF, infliximab; ITT, intent-to-treat; LEF, leflunomide; MTX, methotrexate.